C
Claire Seedhouse
Researcher at University of Nottingham
Publications - 72
Citations - 1994
Claire Seedhouse is an academic researcher from University of Nottingham. The author has contributed to research in topics: Myeloid leukemia & DNA repair. The author has an hindex of 25, co-authored 67 publications receiving 1792 citations. Previous affiliations of Claire Seedhouse include Nottingham City Hospital & Nottingham University Hospitals NHS Trust.
Papers
More filters
Journal ArticleDOI
The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia.
Claire Seedhouse,Rowena Bainton,Michael D. Lewis,Alexander Harding,Nigel H. Russell,Emma Das-Gupta +5 more
TL;DR: Evidence of a protective effect against AML in individuals with at least one copy of the variant XRCC1 399Gln allele compared with those homozygous for the common allele is provided.
Journal ArticleDOI
Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia.
TL;DR: The results strongly suggest that DNA double-strand breaks and their repair are important in the pathogenesis of both de novo and t-AML, a disease that is characterized by genetic instability.
Journal ArticleDOI
Vascular Endothelial Growth Factor Induction by Prostaglandin E2 in Human Airway Smooth Muscle Cells Is Mediated by E Prostanoid EP2/EP4 Receptors and SP-1 Transcription Factor Binding Sites
TL;DR: It is suggested that PGE2 increases VEGF transcriptionally and involves the Sp-1 binding site via a cAMP-dependent mechanism involving EP2 and EP4 receptors.
Journal ArticleDOI
Targeting XRCC1 Deficiency in Breast Cancer for Personalized Therapy
Rebeka Sultana,Tarek Mohamed Ahmed Abdel-Fatah,Rachel Abbotts,Claire Hawkes,Nada Albarakati,Claire Seedhouse,Graham Ball,Stephen Chan,Emad A. Rakha,Ian O. Ellis,Srinivasan Madhusudan +10 more
TL;DR: This is the first study to show that XRCC1 deficiency in breast cancer results in an aggressive phenotype and that XSRC1 deficiency could also be exploited for a novel synthetic lethality application using DSB repair inhibitors.
Journal ArticleDOI
Synthetic lethal targeting of DNA double‐strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors
Rebeka Sultana,Daniel R. McNeill,Rachel Abbotts,Mohammed Z. Mohammed,Małgorzata Z. Zdzienicka,Haitham Qutob,Claire Seedhouse,Charles A. Laughton,Peter Fischer,Poulam M. Patel,David M. Wilson,Srinivasan Madhusudan +11 more
TL;DR: The ability of APE1 inhibitors to induce synthetic lethality (SL) in a panel of DNA double‐strand break (DSB) repair deficient and proficient cells is investigated andAPE1 is a promising SL target in cancer.